Kathryn Chapman

Executive Manager, Milner Therapeutics Consortium

Kathryn’s joined the consortium in 2016, which aims to connect the intellectual know-how of entire academic institutions in Cambridge with the drug-developing capacity of the pharmaceutical industry to deliver better therapies. Prior to that, she was Head of Innovation and Translation at the NC3Rs, whose aim is to increase the availability of new technologies and approaches which reduce animal use across the biosciences. While there, she initiated and directed the NC3Rs challenge-led open innovation platform, CRACK IT which aims to increase cross-discipline and cross-sector industry/academic partnerships in applied research and commercialize 3Rs technologies.